{"id":"https://openalex.org/W1963676290","doi":"https://doi.org/10.1159/000205193","title":"Alpha Interferon Dose-Dependent Suppression of Secondary Clones in a Patient with Philadelphia-Positive Chronic Myelogenous Leukemia","display_name":"Alpha Interferon Dose-Dependent Suppression of Secondary Clones in a Patient with Philadelphia-Positive Chronic Myelogenous Leukemia","publication_year":2009,"publication_date":"2009-02-20","ids":{"openalex":"https://openalex.org/W1963676290","doi":"https://doi.org/10.1159/000205193","mag":"1963676290","pmid":"https://pubmed.ncbi.nlm.nih.gov/2109455"},"language":"en","primary_location":{"id":"doi:10.1159/000205193","doi":"https://doi.org/10.1159/000205193","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000205193","pdf_url":null,"source":{"id":"https://openalex.org/S182948766","display_name":"Acta Haematologica","issn_l":"0001-5792","issn":["0001-5792","1421-9662"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta Haematologica","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004302802","display_name":"David F. Claxton","orcid":"https://orcid.org/0000-0001-9209-2405","observed_orcids":["https://orcid.org/0000-0001-9209-2405"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Claxton","raw_affiliation_strings":["Department of Clinical Immunology and Biological Therapy, University of Texas, M.D. Anderson Cancer Center, Houston"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Immunology and Biological Therapy, University of Texas, M.D. Anderson Cancer Center, Houston","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop Kantarjian","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100688040","display_name":"Jos\u00e9 Manuel Trujillo","orcid":"https://orcid.org/0000-0003-1772-0285","observed_orcids":["https://orcid.org/0000-0003-1772-0285"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jose M. Trujillo","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111569636","display_name":"Jordan U. Gutterman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jordan U. Gutterman","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5011529063","display_name":"Moshe Talpaz","orcid":"https://orcid.org/0000-0003-3361-3981","observed_orcids":["https://orcid.org/0000-0003-3361-3981"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Moshe Talpaz","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.07631806,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"3","first_page":"149","last_page":"151"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.7620000243186951},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9449999928474426},{"id":"https://openalex.org/keywords/philadelphia-chromosome","display_name":"Philadelphia chromosome","score":0.9179999828338623},{"id":"https://openalex.org/keywords/clonal-evolution","display_name":"clonal evolution","score":0.6970000267028809},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.8799999952316284},{"id":"https://openalex.org/keywords/chromosome-evolution","display_name":"karyotype evolution","score":0.9300000071525574},{"id":"https://openalex.org/keywords/chronic-phase","display_name":"chronic phase","score":0.7379999756813049},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.4880000054836273}],"concepts":[{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.8758764266967773},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.61957848072052},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.6071262359619141},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5896981358528137},{"id":"https://openalex.org/C2781228144","wikidata":"https://www.wikidata.org/wiki/Q6046441","display_name":"Interferon alfa","level":4,"score":0.5058326721191406},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5011286735534668},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.48161691427230835},{"id":"https://openalex.org/C2909145159","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Blast Crisis","level":3,"score":0.456572562456131},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.35773229598999023}],"mesh":[{"descriptor_ui":"D002999","descriptor_name":"Clone Cells","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007370","descriptor_name":"Interferon Type I","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007370","descriptor_name":"Interferon Type I","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007621","descriptor_name":"Karyotyping","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1159/000205193","doi":"https://doi.org/10.1159/000205193","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000205193","pdf_url":null,"source":{"id":"https://openalex.org/S182948766","display_name":"Acta Haematologica","issn_l":"0001-5792","issn":["0001-5792","1421-9662"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta Haematologica","raw_type":"journal-article"},{"id":"pmid:2109455","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2109455","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta haematologica","raw_type":"Case Reports"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2092017371","https://openalex.org/W2006531788","https://openalex.org/W2257120478","https://openalex.org/W2049181628","https://openalex.org/W2091237754","https://openalex.org/W1851600330","https://openalex.org/W2433244619","https://openalex.org/W2038570020","https://openalex.org/W2485594933","https://openalex.org/W2003682565"],"abstract_inverted_index":{"A":[0],"patient":[1],"whose":[2],"chronic":[3,22],"myelogenous":[4],"leukemia":[5],"(CML)":[6],"was":[7],"treated":[8],"with":[9],"interferon":[10],"alpha":[11],"(IFN-alpha)":[12],"is":[13,56],"described.":[14],"The":[15,40,51],"disease":[16],"showed":[17],"karyotypic":[18],"evolution":[19,55],"during":[20],"the":[21,25,43,59],"phase":[23],"and":[24],"later":[26],"myeloid":[27],"acceleration.":[28],"Both":[29],"of":[30,46,53,61],"these":[31],"secondary":[32],"clonal":[33,54],"phenomena":[34],"responded":[35],"to":[36,49],"IFN-alpha":[37],"dose":[38,44],"escalation.":[39],"case":[41],"illustrates":[42],"dependence":[45],"CML":[47],"responses":[48],"IFN-alpha.":[50],"phenomenon":[52],"discussed":[57],"in":[58],"context":[60],"this":[62],"patient's":[63],"disease.":[64]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}